



Financial Tear Sheet

Corporate Profile

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.

Stock Information

EBS (Common Stock)	
Exchange	NYSE (US Dollar)
Price	\$70.76
Change (%)	▲ 1.02 (1.46%)
Volume	265,345
52 Week Low	\$37.89
Market Cap	\$3,552,908,205
Rolling EPS	1.96
PE Ratio	35.658
Shares Outstanding	50,945,056

Data as of 11/21/18 4:02 p.m. ET



Recent Headlines & Events

11/19/18

Emergent BioSolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus

11/06/18

Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences

11/01/18

Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months of 2018

Date	Title
11/27/18 9:30 a.m. ET	<u>Emergent BioSolutions Inc. at Piper Jaffray – 30th Annual Healthcare Conference</u>
12/03/18	<u>Emergent BioSolutions Inc. at Mizuho – Global Mizuho Investor Conference</u>
12/12/18	<u>Emergent BioSolutions Inc. at BMO Capital Markets – 2018 Prescriptions for Success Healthcare Conference</u>

SEC Filings

Filing Date	Form
11/21/18	4
11/13/18	CT ORDER
11/13/18	CT ORDER
11/08/18	4

Data provided by Nasdaq. Minimum 15 minutes delayed.

Primary IR Contact

Robert G. Burrows
Vice President,
Investor Relations
Emergent BioSolutions Inc.
Phone: (240) 631 3280
Fax: (240) 413-1917
E-mail: burrowsr@ebsi.com